Search results
Results from the WOW.Com Content Network
Granulocytopenia, which is frequently associated with chemotherapy, is a significant risk factor for infections, with individuals who have lower granulocyte counts having a higher incidence of infections. [28] Genetic differences in the innate immune system may also affect the duration and severity of infectious episodes in people with neutropenia.
Meaning, if you’re under 65 and aren’t immunocompromised, the CDC recommends getting an updated COVID-19 vaccine once a year. Unlike the flu vaccine, the CDC doesn’t suggest getting an ...
The word leukemia, which means 'white blood', is derived from the characteristic high white blood cell count that presents in most affected people before treatment. The high number of white blood cells is apparent when a blood sample is viewed under a microscope, with the extra white blood cells frequently being immature or dysfunctional. The ...
Immunoglobulin therapy is the use of a mixture of antibodies (normal human immunoglobulin) to treat several health conditions. [13] [14] These conditions include primary immunodeficiency, immune thrombocytopenic purpura, chronic inflammatory demyelinating polyneuropathy, Kawasaki disease, certain cases of HIV/AIDS and measles, Guillain–Barré syndrome, and certain other infections when a ...
Cancer immunotherapy (immuno-oncotherapy) is the stimulation of the immune system to treat cancer, improving the immune system's natural ability to fight the disease. [1] It is an application of the fundamental research of cancer immunology (immuno-oncology) and a growing subspecialty of oncology. Cancer immunotherapy exploits the fact that ...
An excess of white blood cells is usually due to infection or inflammation. Less commonly, a high white blood cell count could indicate certain blood cancers or bone marrow disorders. The number of leukocytes in the blood is often an indicator of disease, and thus the white blood cell count is an important subset of the complete blood count.
The FDA authorized a second booster for people 50 and older. The shot can be administered starting at least four months after receiving the first booster.
EPOCH (chemotherapy) EPOCH is an intensive chemotherapy regimen intended for treatment of aggressive non-Hodgkin's lymphoma. [1][2] It is often combined with rituximab. In this case it is called R-EPOCH or EPOCH-R.The R-EPOCH regimen consists of: Rituximab: an anti- CD20 monoclonal antibody, which has the ability to kill B cells, be they normal ...